일중음의 인체 전립선암 세포에 대한 성장억제 효과 = Cytotoxic Effect of Iljoong-eum on Human Prostate Cancer Cells

다국어 초록 (Multilingual Abstract)

Objectives : The study was intended to investigate whether Iljoong-eum (IJE) significantly affects proliferation and growth of prostate cancer cells. Materials and Methods : In vitro, after the treatment of DU-145 and PC-3 cells with IJE, we performed Sulforhodamine B (SRB) method. In vivo, a total of 8 male nude mice subcutaneously transplanted with the PC-3 cell line were divided in 2 groups. An experimental group was given IJE orally at a dose of 4.29ml/kg per day from the 8th to 31st day following tumor injection. All mice were observed for 31 days, and sacrificed by CO2 gas asphyxiation at the end of the experiment. The mean tumor volume and body weight of both groups were compared using Student's t-tests. Results : In vitro, IJE inhibited significantly proliferation and growth of DU-145 cells and PC-3 cells. In vivo, IJE inhibited significantly proliferation and growth of PC-3 cells xenografted into athymic nude mice. Conclusions : Our data has shown that IJE is effective in suppressing the growth rate of prostate cancer cells.

참고문헌 (Reference)

1 김옥희, "천연물의 항암작용에 관한 연구" 6 : 201-207, 1993

2 박철, "참나무 목초액에 의한 전립선암세포의 apoptosis 유발기전에 관한 연구" 17 (17): 85-90, 2003

3 김옥희, "인체 암 세포주를 이용한 천연물의 항암작용 검색" 5 : 188-194, 1992

4 황도연, "방약합편" 남산당 166-168, 1986

5 권강범, "남성호르몬 비의존형 전립선 암세포에서 敗醬 추출물의 세포고사 유도 효과" 대한동의병리학회 18 (18): 1661-1665, 2004

6 이형재, "남성호르몬 비의존형 전립선 암세포에서 托裏消毒飮 추출물의 세포고사 유도 효과" 대한동의병리학회 20 (20): 861-865, 2006

7 김옥희, "고삼 등 천연물의 in vitro 항암작용 검색에 관한 연구" 7 : 151-156, 1994

8 권강범, "白芍藥 추출물의 전립선 암세포 고사 유도 효과 및 기전 연구" 대한동의병리학회 18 (18): 1617-1621, 2004

9 전국한의과대학본초학교수, "本草學" 영림사 193-195, 1991

10 新文豐出版公司, "新編中藥大辭典(上)" 新文豐出版公司 51-52, 1985

11 손기정, "慢性前立腺炎에 대한 加味敗醬地黃湯의 임상적 효과" 대한동의병리학회 17 (17): 958-961, 2003

12 Boland MP, "Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells" 275 : 25231-25238, 2000

13 Moos PJ, "Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits" 9 : 687-697, 1998

14 Hsieh TC, "Prevention and management of prostate cancer using PC-SPES: a scientific perspective" 132 (132): 3513S-3517S, 2002

15 Hudes GR, "Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer" 15 : 3156-3163, 1997

16 Kubota T, "PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo" 42 (42): 163-171, 2000

17 Skehan P, "New colorimetric cytotoxicity assay for anticancer-drug screening" 82 (82): 1107-1112, 1990

18 Pound CR, "Natural history of progression after PSA elevation following radical prostatectomy" 281 (281): 1591-1597, 1999

19 Bonham M, "Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma" 62 (62): 3920-3924, 2002

20 de la Taille A, "Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer" 164 (164): 1229-1234, 2000

21 Dahllof B, "Estramustine depolymerizes microtubules by binding to tubulin" 53 : 4573-4581, 1999

22 Bonham MJ, "Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition" 94 (94): 1641-1647, 2002

23 Eisenberger MA, "Chemotherapy for prostatic carcinoma" 6 : 303-310, 1988

24 Osterling JE, "Cancer of the prostate in: Cancer:principles and practice of oncology" Lippincott -Raven 1332-1339, 1997

25 Jemal A, "Annual report to the nation on the status of cancer, 1975-2001" 101 (101): 3-27, 2004

26 Ministry of Health and Welfare, "2004 Annual Report of the Central Cancer Registry in Korea" 2005